Skip to main content
Erschienen in: Clinical Orthopaedics and Related Research® 11/2014

01.11.2014 | Clinical Research

Do Long Term Survivors of Ewing Family of Tumors Experience Low Bone Mineral Density and Increased Fracture Risk?

verfasst von: Gerhard M. Hobusch, MD, Iris Noebauer-Huhmann, MD, PhD, Christoph Krall, PhD, Gerold Holzer, MD, PhD

Erschienen in: Clinical Orthopaedics and Related Research® | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Multimodal treatment regimens for Ewing’s sarcoma have led to survival rates approaching 70% of patients with no metastases at diagnosis. However, these treatments have long-term side effects. Low bone mineral density (BMD) and risk of fractures can occur owing in part to chemotherapy and limited mobility from local control of the primary tumor.

Questions/purposes

We performed this study to answer the following questions: (1) Do long-term survivors of the Ewing family of tumors sustain low BMD? (2) Which factors are associated with BMD in these patients? (3) Do they experience fractures? (4) Are BMD and fractures associated with each other?

Methods

We queried our institutional registry to identify all known survivors of Ewing tumors who were treated before 2005. Of 100 such patients, 67 (67%) responded to a postal survey to participate in this study, and an additional 11 (11%) patients were excluded according to prespecified criteria. In the remaining 56 long-term survivors (27 females, 29 males; mean ± SD age at followup, 32 ± 10 years; mean followup, 15 ± 7 years), BMD was measured by dual-energy x-ray absorptiometry and history of fractures was assessed using a questionnaire. Associations were tested using univariate and multivariate models by stepwise variable selection procedure, including Bonferroni correction.

Results

Thirty-one of 56 (56%) patients had a pathologic BMD. Seven (13%) had osteoporosis and 24 (43%) had osteopenia. Factors related to low BMD after Bonferroni correction were the length of time between surgery and followup and the BMI at followup. Twenty-one patients reported 29 fractures. With the numbers available, BMD levels were not associated with fractures.

Conclusions

We could not confirm some potentially important predictors for fractures to be associated with clinical events of interest. However, the data are valuable as hypothesis-generating pilot data for future, multicenter prospective studies. If BMD changes cannot explain the propensity of fractures, there may be other bone characteristics like microarchitectural changes of bone to more accurately explain the effect.

Level of Evidence

Level IV, prognostic study. See the Instructions for Authors for a complete description of levels of evidence.
Literatur
1.
Zurück zum Zitat Alibhai SMH, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184:918–923.PubMedCrossRef Alibhai SMH, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184:918–923.PubMedCrossRef
2.
Zurück zum Zitat Arikoski P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kröger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocrinol Metab. 1999;84:3174–3181.PubMedCrossRef Arikoski P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kröger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocrinol Metab. 1999;84:3174–3181.PubMedCrossRef
3.
Zurück zum Zitat Azcona C, Burghard E, Ruza E, Gimeno J, Sierrasesúmaga L. Reduced bone mineralization in adolescent survivors of malignant bone tumors: comparison of quantitative ultrasound and dual-energy x-ray absorptiometry. J Pediatr Hematol Oncol. 2003;25:297–302.PubMedCrossRef Azcona C, Burghard E, Ruza E, Gimeno J, Sierrasesúmaga L. Reduced bone mineralization in adolescent survivors of malignant bone tumors: comparison of quantitative ultrasound and dual-energy x-ray absorptiometry. J Pediatr Hematol Oncol. 2003;25:297–302.PubMedCrossRef
4.
Zurück zum Zitat Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab. 1991;73:555–563.PubMedCrossRef Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab. 1991;73:555–563.PubMedCrossRef
5.
Zurück zum Zitat Cauley JA, Harrison SL, Cawthon PM, Ensrud KE, Danielson ME, Orwoll E, Mackey DC. Objective measures of physical activity, fractures and falls: the osteoporotic fractures in men study. J Am Geriatr Soc. 2013;61:1080–1088.PubMedCrossRefPubMedCentral Cauley JA, Harrison SL, Cawthon PM, Ensrud KE, Danielson ME, Orwoll E, Mackey DC. Objective measures of physical activity, fractures and falls: the osteoporotic fractures in men study. J Am Geriatr Soc. 2013;61:1080–1088.PubMedCrossRefPubMedCentral
6.
Zurück zum Zitat Clark EM, Tobias JH, Ness AR. Association between bone density and fractures in children: a systematic review and meta-analysis. Pediatrics. 2006;117:e291–297.PubMedCrossRefPubMedCentral Clark EM, Tobias JH, Ness AR. Association between bone density and fractures in children: a systematic review and meta-analysis. Pediatrics. 2006;117:e291–297.PubMedCrossRefPubMedCentral
7.
Zurück zum Zitat Damron TA, Sim FH, O’Connor MI, Pritchard DJ, Smithson WA. Ewing’s sarcoma of the proximal femur. Clin Orthop Relat Res. 1996;322:232–244.PubMedCrossRef Damron TA, Sim FH, O’Connor MI, Pritchard DJ, Smithson WA. Ewing’s sarcoma of the proximal femur. Clin Orthop Relat Res. 1996;322:232–244.PubMedCrossRef
8.
Zurück zum Zitat Dhakal S, Chen J, McCance S, Rosier R, O’Keefe R, Constine LS. Bone density changes after radiation for extremity sarcomas: exploring the etiology of pathologic fractures. Int J Radiat Oncol Biol Phys. 2011;80:1158–1163.PubMedCrossRef Dhakal S, Chen J, McCance S, Rosier R, O’Keefe R, Constine LS. Bone density changes after radiation for extremity sarcomas: exploring the etiology of pathologic fractures. Int J Radiat Oncol Biol Phys. 2011;80:1158–1163.PubMedCrossRef
10.
Zurück zum Zitat Dunst J, Jürgens H, Sauer R, Pape H, Paulussen M, Winkelmann W, Rübe C. Radiation therapy in Ewing’s sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995;32:919–930.PubMedCrossRef Dunst J, Jürgens H, Sauer R, Pape H, Paulussen M, Winkelmann W, Rübe C. Radiation therapy in Ewing’s sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995;32:919–930.PubMedCrossRef
11.
Zurück zum Zitat Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–120.PubMed Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–120.PubMed
12.
Zurück zum Zitat Fuchs B, Valenzuela RG, Inwards C, Sim FH, Rock MG. Complications in long-term survivors of Ewing sarcoma. Cancer. 2003;98:2687–2692.PubMedCrossRef Fuchs B, Valenzuela RG, Inwards C, Sim FH, Rock MG. Complications in long-term survivors of Ewing sarcoma. Cancer. 2003;98:2687–2692.PubMedCrossRef
13.
Zurück zum Zitat Fuchs B, Valenzuela RG, Sim FH. Pathologic fracture as a complication in the treatment of Ewing’s sarcoma. Clin Orthop Relat Res. 2003;415:25–30.PubMedCrossRef Fuchs B, Valenzuela RG, Sim FH. Pathologic fracture as a complication in the treatment of Ewing’s sarcoma. Clin Orthop Relat Res. 2003;415:25–30.PubMedCrossRef
14.
Zurück zum Zitat Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008;12:157–170.PubMedCrossRef Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008;12:157–170.PubMedCrossRef
15.
Zurück zum Zitat Genant HK, Grampp S, Glüer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Van Kuijk C. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res. 1994;9:1503–1514.PubMedCrossRef Genant HK, Grampp S, Glüer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Van Kuijk C. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res. 1994;9:1503–1514.PubMedCrossRef
16.
Zurück zum Zitat Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, Smith SM, Stovall M, Hammond S, Robison LL, Oeffinger KC. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst. 2010;102:1272–1283.PubMedCrossRefPubMedCentral Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, Smith SM, Stovall M, Hammond S, Robison LL, Oeffinger KC. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst. 2010;102:1272–1283.PubMedCrossRefPubMedCentral
17.
Zurück zum Zitat Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, Weaver C. Peak bone mass. Osteoporos Int. 2000;11:985–1009.PubMedCrossRef Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, Weaver C. Peak bone mass. Osteoporos Int. 2000;11:985–1009.PubMedCrossRef
18.
Zurück zum Zitat Henderson RC, Madsen CD, Davis C, Gold SH. Bone density in survivors of childhood malignancies. J Pediatr Hematol Oncol. 1996;18:367–371.PubMedCrossRef Henderson RC, Madsen CD, Davis C, Gold SH. Bone density in survivors of childhood malignancies. J Pediatr Hematol Oncol. 1996;18:367–371.PubMedCrossRef
19.
Zurück zum Zitat Holzer G, Krepler P, Koschat MA, Grampp S, Dominkus M, Kotz R. Bone mineral density in long-term survivors of highly malignant osteosarcoma. J Bone Joint Surg Br. 2003;85:231–237.PubMedCrossRef Holzer G, Krepler P, Koschat MA, Grampp S, Dominkus M, Kotz R. Bone mineral density in long-term survivors of highly malignant osteosarcoma. J Bone Joint Surg Br. 2003;85:231–237.PubMedCrossRef
20.
Zurück zum Zitat Holzer G, von Skrbensky G, Holzer LA, Pichl W. Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength. J Bone Miner Res. 2009;24:468–474.PubMedCrossRef Holzer G, von Skrbensky G, Holzer LA, Pichl W. Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength. J Bone Miner Res. 2009;24:468–474.PubMedCrossRef
21.
Zurück zum Zitat Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185–1194.PubMedCrossRef Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185–1194.PubMedCrossRef
22.
Zurück zum Zitat Jürgens H, Bier V, Dunst J, Harms D, Jobke A, Kotz R, Kühl J, Müller-Weihrich S, Ritter J, Salzer-Kuntschik M. [The German Society of Pediatric Oncology Cooperative Ewing Sarcoma Studies CESS 81/86: report after 6 ½ years][in German]. Klin Padiatr. 1988;200:243–252.PubMedCrossRef Jürgens H, Bier V, Dunst J, Harms D, Jobke A, Kotz R, Kühl J, Müller-Weihrich S, Ritter J, Salzer-Kuntschik M. [The German Society of Pediatric Oncology Cooperative Ewing Sarcoma Studies CESS 81/86: report after 6 ½ years][in German]. Klin Padiatr. 1988;200:243–252.PubMedCrossRef
23.
Zurück zum Zitat Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European foundation for osteoporosis and bone disease. The Scientific Advisory Board and the Board of National Societies. Osteoporos Int. 1996;6:256–261.PubMedCrossRef Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European foundation for osteoporosis and bone disease. The Scientific Advisory Board and the Board of National Societies. Osteoporos Int. 1996;6:256–261.PubMedCrossRef
25.
Zurück zum Zitat Kaste SC, Ahn H, Liu T, Liu W, Krasin MJ, Hudson MM, Spunt SL. Bone mineral density deficits in pediatric patients treated for sarcoma. Pediatr Blood Cancer. 2008;50:1032–1038.PubMedCrossRef Kaste SC, Ahn H, Liu T, Liu W, Krasin MJ, Hudson MM, Spunt SL. Bone mineral density deficits in pediatric patients treated for sarcoma. Pediatr Blood Cancer. 2008;50:1032–1038.PubMedCrossRef
26.
Zurück zum Zitat Kelly J, Damron T, Grant W, Anker C, Holdridge S, Shaw S, Horton J, Cherrick I, Spadaro J. Cross-sectional study of bone mineral density in adult survivors of solid pediatric cancers. J Pediatr Hematol Oncol. 2005;27:248–253.PubMedCrossRef Kelly J, Damron T, Grant W, Anker C, Holdridge S, Shaw S, Horton J, Cherrick I, Spadaro J. Cross-sectional study of bone mineral density in adult survivors of solid pediatric cancers. J Pediatr Hematol Oncol. 2005;27:248–253.PubMedCrossRef
27.
Zurück zum Zitat Kudlacek S, Schneider B, Peterlik M, Leb G, Klaushofer K, Weber K, Woloszczuk W, Willvonseder R; Austrian Study Group on Normative Values of Bone Metabolism. Normative data of bone mineral density in an unselected adult Austrian population. Eur J Clin Invest. 2003;33:332–339.PubMedCrossRef Kudlacek S, Schneider B, Peterlik M, Leb G, Klaushofer K, Weber K, Woloszczuk W, Willvonseder R; Austrian Study Group on Normative Values of Bone Metabolism. Normative data of bone mineral density in an unselected adult Austrian population. Eur J Clin Invest. 2003;33:332–339.PubMedCrossRef
28.
Zurück zum Zitat Matkovic V, Jelic T, Wardlaw GM, Ilich JZ, Goel PK, Wright JK, Andon MB, Smith KT, Heaney RP. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: inference from a cross-sectional model. J Clin Invest. 1994;93:799–808.PubMedCrossRefPubMedCentral Matkovic V, Jelic T, Wardlaw GM, Ilich JZ, Goel PK, Wright JK, Andon MB, Smith KT, Heaney RP. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: inference from a cross-sectional model. J Clin Invest. 1994;93:799–808.PubMedCrossRefPubMedCentral
29.
Zurück zum Zitat Morin S, Tsang JF, Leslie WD. Weight and body mass index predict bone mineral density and fractures in women aged 40 to 59 years. Osteoporos Int. 2009;20:363–370.PubMedCrossRef Morin S, Tsang JF, Leslie WD. Weight and body mass index predict bone mineral density and fractures in women aged 40 to 59 years. Osteoporos Int. 2009;20:363–370.PubMedCrossRef
30.
Zurück zum Zitat Muszynska-Roslan K, Konstantynowicz J, Panasiuk A, Krawczuk-Rybak M. Is the treatment for childhood solid tumors associated with lower bone mass than that for leukemia and Hodgkin disease? Pediatr Hematol Oncol. 2009;26:36–47.PubMedCrossRef Muszynska-Roslan K, Konstantynowicz J, Panasiuk A, Krawczuk-Rybak M. Is the treatment for childhood solid tumors associated with lower bone mass than that for leukemia and Hodgkin disease? Pediatr Hematol Oncol. 2009;26:36–47.PubMedCrossRef
31.
Zurück zum Zitat Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H; European Intergroup Cooperative Ewing’s Sarcoma Study-92. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment: cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26:4385–4393.PubMedCrossRef Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H; European Intergroup Cooperative Ewing’s Sarcoma Study-92. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment: cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26:4385–4393.PubMedCrossRef
32.
Zurück zum Zitat Pirker-Frühauf UM, Friesenbichler J, Urban EC, Obermayer-Pietsch B, Leithner A. Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma. Clin Orthop Relat Res. 2012;470:2874–2885.PubMedCrossRefPubMedCentral Pirker-Frühauf UM, Friesenbichler J, Urban EC, Obermayer-Pietsch B, Leithner A. Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma. Clin Orthop Relat Res. 2012;470:2874–2885.PubMedCrossRefPubMedCentral
33.
Zurück zum Zitat Ponnapakkam T, Katikaneni R, Nichols T, Tobin G, Sakon J, Matsushita O, Gensure RC. Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone. J Endocrinol Invest. 2011;34:e392–397.PubMed Ponnapakkam T, Katikaneni R, Nichols T, Tobin G, Sakon J, Matsushita O, Gensure RC. Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone. J Endocrinol Invest. 2011;34:e392–397.PubMed
34.
Zurück zum Zitat Ruza E, Sierrasesúmaga L, Azcona C, Patiño-Garcia A. Bone mineral density and bone metabolism in children treated for bone sarcomas. Pediatr Res. 2006;59:866–871.PubMedCrossRef Ruza E, Sierrasesúmaga L, Azcona C, Patiño-Garcia A. Bone mineral density and bone metabolism in children treated for bone sarcomas. Pediatr Res. 2006;59:866–871.PubMedCrossRef
35.
Zurück zum Zitat Salzer-Kuntschik M, Brand G, Delling G. [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors][in German]. Pathologe. 1983;4:135–141.PubMed Salzer-Kuntschik M, Brand G, Delling G. [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors][in German]. Pathologe. 1983;4:135–141.PubMed
36.
Zurück zum Zitat Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19:3306–3311.PubMed Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19:3306–3311.PubMed
37.
Zurück zum Zitat Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:2815–2822.PubMedCrossRef Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:2815–2822.PubMedCrossRef
38.
Zurück zum Zitat Slosman DO, Rizzoli R, Pichard C, Donath A, Bonjour JP. Longitudinal measurement of regional and whole body bone mass in young healthy adults. Osteoporos Int. 1994;4:185–190.PubMedCrossRef Slosman DO, Rizzoli R, Pichard C, Donath A, Bonjour JP. Longitudinal measurement of regional and whole body bone mass in young healthy adults. Osteoporos Int. 1994;4:185–190.PubMedCrossRef
40.
Zurück zum Zitat Tenardi RD, Frühwald MC, Jürgens H, Hertroijs D, Bauer J. Nutritional status of children and young adults with Ewing sarcoma or osteosarcoma at diagnosis and during multimodality therapy. Pediatr Blood Cancer. 2012;59:621–626.PubMedCrossRef Tenardi RD, Frühwald MC, Jürgens H, Hertroijs D, Bauer J. Nutritional status of children and young adults with Ewing sarcoma or osteosarcoma at diagnosis and during multimodality therapy. Pediatr Blood Cancer. 2012;59:621–626.PubMedCrossRef
41.
Zurück zum Zitat Virolainen P, Inoue N, Nagao M, Frassica FJ, Chao EY. The effect of a doxorubicin, cisplatin and ifosfamide combination chemotherapy on bone turnover. Anticancer Res. 2002;22:1971–1975.PubMed Virolainen P, Inoue N, Nagao M, Frassica FJ, Chao EY. The effect of a doxorubicin, cisplatin and ifosfamide combination chemotherapy on bone turnover. Anticancer Res. 2002;22:1971–1975.PubMed
42.
Zurück zum Zitat Wang TM, Shih C. Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide. Acta Anat (Basel). 1986;127:93–99.PubMedCrossRef Wang TM, Shih C. Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide. Acta Anat (Basel). 1986;127:93–99.PubMedCrossRef
Metadaten
Titel
Do Long Term Survivors of Ewing Family of Tumors Experience Low Bone Mineral Density and Increased Fracture Risk?
verfasst von
Gerhard M. Hobusch, MD
Iris Noebauer-Huhmann, MD, PhD
Christoph Krall, PhD
Gerold Holzer, MD, PhD
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
Clinical Orthopaedics and Related Research® / Ausgabe 11/2014
Print ISSN: 0009-921X
Elektronische ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-014-3777-5

Weitere Artikel der Ausgabe 11/2014

Clinical Orthopaedics and Related Research® 11/2014 Zur Ausgabe

Symposium: 2013 Musculoskeletal Infection Society

Antimicrobial Distribution From Local Delivery Depends on Dose

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.